Serious Disease Genetic Testing Claims More Likely To Prompt FTC Action
This article was originally published in The Gray Sheet
Executive Summary
The Federal Trade Commission's limited oversight of regional laboratories and genetic test promotional claims for non-life-threatening diseases is eliciting concern from the HHS Secretary's Advisory Committee on Genetics, Health & Society